Cost Control, Transparency & Pharma Health Care Policy

Overview: Understanding the flow of funds is critical in grasping the financial relationships in healthcare concerning pharmaceuticals.
- Key Players:
- Drug Manufacturer: Responsible for producing medication.
- Health Plan: Manages drug benefits; involved in negotiating formulary placements.
- Pharmacy Benefit Manager (PBM): Facilitates medication access through insurance providers.
- Wholesaler: Distributes pharmaceutical products and receives payments for drugs and dispensing fees.
Key Concepts:
- Rebates: Drug manufacturers negotiate rebates with PBMs, affecting overall drug costs and payments.
- The Spread: The difference between payments within the flow, indicating profit margins among participants.

Case Study: Mark Cuban's Cost Plus Drugs
- Quote: "My joy comes from screwing the PBMs."
- Insight: Cast as a David vs. Goliath narrative; highlights the dominance of PBMs in the market (90% control).
- Transparency Practice:
- Pricing Strategy: Reveals drug prices, markup of 15%, fees ($5 for pharmacist reviews, $5 for shipping), and displays price lists online.
- Potential Savings: Approximately $1.29 billion in 2020 if Medicare generic drug pricing mirrored that on CostPlusDrugs.com.
- Analysis: Discusses pros and cons of increased transparency in drug pricing.

Mandate Overview: Hospitals are required to display price data for 300 shoppable services that can be scheduled in advance.
- Compliance: Per an AHA study, compliance was 5% in July 2021, which improved to 50-66% by October 2022.
- Penalties: Hospitals face penalties of up to $300 per day for non-compliance; however, costs incurred in compliance may exceed potential penalties.
- Implementation Date: The rule went into effect in January 2021, following the Trump Administration's policy decisions from 2018.
Research Insights:
- Study Insight: Issues arise from relying too heavily on claims data over clinical processes in setting transparency guidelines.
- Proposals for Improvement:
- Hospitals to disclose a range of negotiated prices rather than exact figures, considering patient risk factors and service scope.

Trends: notable increase in provider network mergers, both vertical and horizontal integration, leading to large healthcare systems such as HCA, Ascension, and Trinity Health across multiple states.
Risks:
- Reduction in competition results in increased healthcare spending and costs for patients and employers.
- Challenges related to quality of care for underserved and rural populations.
- Potential job impacts, including lower wages and staffing reductions.
Regulatory Response: The Department of Justice (DOJ) and Federal Trade Commission (FTC) have indicated increased scrutiny on mergers to challenge anti-competitive practices.

Case Study: Steward Healthcare's Bankruptcy
- Background: Acquisition by Cerberus Private Equity in 2010; strategic moves led to financial strain and subsequent filing for bankruptcy in Texas in May 2024.
- Impact on Healthcare:
- Loss of critical hospital facilities and long-term implications for local communities.
- Real estate management firm Medical Properties Trust now rents facilities to Steward, worsening financial viability.
- Policy Discussions: Questions of accountability arise, concerning the initial approval of the PE acquisitions and implications for future healthcare regulations.

Issues of Cost, Quality, Performance & Ethics: Discussions on ensuring quality and ethical healthcare delivery.
Reading Assignments:
- B&G&W-G Chapter 6: Medical Ethics and Rationing of Care
- Barr Chapters 2 & 3: Principles of Public Health Ethics
Upcoming Discussion: Ethics Fishbowl scheduled for October 22nd!